Condition: Breast Cancer · Sponsor: Risen (Suzhou) Pharma Tech Co., Ltd.
This study is a randomised, open-label, multicentre phase III clinical study evaluating the efficacy and safety of JS105 combined with Dalpiciclib and Fulvestrant compared with Dalpiciclib and Fulvestrant in patients with PIK3CA-mutated, HR-positive, HER2-negative recurrent or metastatic breast cancer.
This description comes directly from the study's public registry record.
Qianna Zhan, Master · 13526615319 · zhan@junshipharma.com
Huiyu Lan, Master · 15000239047 · huiyu_lan@junshipharma.com
Always discuss trial participation with your own doctor first.
| Chinese Acadamy of Medical Sciences and Peking Union Medical College | Beijing, Beijing Municipality, China | Recruiting |
| Henan Provincial Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07207070